Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Oncometabolite D-2-Hydroxyglutarate Inhibits ALKBH DNA Repair Enzymes and Sensitizes IDH Mutant Cells to Alkylating Agents.

Cell reports - 22 Dec 2015

Wang Pu, Wu Jing, Ma Shenghong, Zhang Lei, Yao Jun, Hoadley Katherine A, Wilkerson Matthew D, Perou Charles M, Guan Kun-Liang, Ye Dan, Xiong Yue

Abstract excerpt

Chemotherapy of a combination of DNA alkylating agents, procarbazine and lomustine (CCNU), and a microtubule poison, vincristine, offers a significant benefit to a subset of glioma patients. The benefit of this regimen, known as PCV, was recently linked to IDH mutation that occurs frequently in glioma and produces D-2-hydroxyglutarate (D-2-HG), a competitive inhibitor of α-ketoglutarate (α-KG). We report here...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alkylating Agents
Share to Dioxygenases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to DNA Repair Enzymes

Share to Glutarates

Share to Isocitrate Dehydrogenase

Share to Ketoglutaric Acids

Share to RNA Interference

Share to RNA, Small Interfering

Source

Open in PubMed Open full text

Identifiers

PMID: 26686626
DOI: 10.1016/j.celrep.2015.11.029
PMCID: PMC4694633

Genes

ALKBH2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Oncometabolite D-2-Hydroxyglutarate Inhibits ALKBH DNA Repair Enzymes and Sensitizes IDH Mutant Cells to Alkylating Agents.PMID 26686626Read ↗

DNA damage in IDH-mutant gliomas: mechanisms and clinical implications.Semantic proximity Read ↗

IDH mutations in cancer and progress toward development of targeted therapeutics.Semantic proximity Read ↗

2-Hydroxyglutarate produced by neomorphic IDH mutations suppresses homologous recombination and induces PARP inhibitor sensitivitySemantic proximity Read ↗

D-2-Hydroxyglutarate in Glioma Biology.Semantic proximity Read ↗

Oncometabolite 2-hydroxyglutarate suppresses basal protein levels of DNA polymerase beta that enhances alkylating agent and PARG inhibition induced cytotoxicity.Semantic proximity Read ↗

Metabolism, Activity, and Targeting of D- and L-2-Hydroxyglutarates.Semantic proximity Read ↗

R-2-hydroxyglutarate-mediated inhibition of KDM4A compromises telomere integritySemantic proximity Read ↗

Chemosensitivity of IDH1-Mutated Gliomas Due to an Impairment in PARP1-Mediated DNA Repair.Semantic proximity Read ↗

The Emerging Role of D-2-Hydroxyglutarate as an Oncometabolite in Hematolymphoid and Central Nervous System NeoplasmsSemantic proximity Read ↗

KDM6 Enzymes are the Mechanistic Targets of Mutant IDH that Dictate Replication Stress SensitivitySemantic proximity Read ↗

Targeting Isocitrate Dehydrogenase Mutations in Cancer: Emerging Evidence and Diverging Strategies.Semantic proximity Read ↗

Targeting IDH1/2 mutant cancers with combinations of ATR and PARP inhibitorsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.